 |
|
|
| |
Glecaprevir/Pibrentasvir Fixed-Dose Combination for
8 or 12 Weeks in Patients Co-Infected With HCV and HIV-1:
A Sub-Analysis of the Phase 3 ENDURANCE-1 Study
|
| |
| |
Reported by Jules Levin
International AIDS Society (IAS) Conference on HIV Science, 23–26 July 2017, Paris, France
Massimo Puoti 1, Jordan J Feld2, Stanley Wang3, Rafi Bruck4, Christophe Moreno5, Jean-Francois Dufour6,
Hermann Laferl7, Frederik Nevens8, Ruth Soto-Malave9, Franco Felizarta10, Beat Müllhaupt11,
Stuart C Gordon12, Chih-Wei Lin3, Teresa I Ng3, Bo Fu3, Roger Trinh3, Federico Mensa3
1AO Ospedale Niguarda Ca' Granda, Milan, Italy; 2Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 3AbbVie Inc., North Chicago, Illinois, United States; 4Tel Aviv Medical Center, Tel Aviv, Israel; 5CUB Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium; 6Hepatology, University Clinic for Visceral Surgery and Medicine, Bern University Hospital, Bern, Switzerland; 7Kaiser Franz Josef Hospital, 4th Medical Department With Infecti ous Diseases and Tropical Medicine, Vienna, Austria; 8University Hospitals KU, Leuven, Belgium; 9University of Puerto Rico, San Juan, Puerto Rico; 10Private Practi ce, Bakersfi eld, California, United States; 11University Hospital, Zurich, Switzerland; 12Henry Ford Health System, Detroit, Michigan, United States
CROI: GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS - (02/20/17)
|
| |
|
|
|
|
|
